unknown
Stage
1
Investors
About
Empros Pharma is developing EMP16, an oral weight-loss maintenance pharmaceutical that combines orlistat and acarbose in a controlled-release formulation to block fat and carbohydrate absorption locally in the gut. The company is pursuing clinical development (Phase 2b data reported) with the aim of a first-line, safe oral treatment for obesity.
Explore Empros Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.